pharmaphorum

AUGUST 25, 2022

Both bispecifics have arisen out of J&J’s longstanding alliance with Genmab, which also generated anti-CD38 blockbuster Darzalex (daratumumab). Tecvayli previously scored a priority medicines (PRiME) designation from the EMA and a breakthrough-therapy tag from the FDA.

Antibody 94

Antibody Marketing Drugs Medicine 94

pharmaphorum

APRIL 20, 2021

NICE’s final appraisal document for Kesimpta will be followed by technology appraisal guidance (TAG) that will pave the way for NHS prescribing in England and Wales. The Scottish Medicines Consortium is expected to publish its final advice on the drug later this year. billion in sales in 2028.

Sales 109

Sales Medicine Drugs Marketing 109

pharmaphorum

JULY 25, 2022

The new drug is one of two bispecifics for multiple myeloma in the late-stage pipeline of J&J’s Janssen division stemming from its longstanding and fertile collaboration with Danish biotech Genmab, along with talquetamab which binds to CD3 and GPRC5D.

Antibody 52

Antibody Medicine Drugs Trials 52

Drug Discovery World

NOVEMBER 13, 2023

Dennis Verzijl, PhD, Principal Scientist, Genmab, on: ‘Kinetic antibody characterisation on challenging targets’. Fabian Mohr, PhD, Vice President Research & Development, IBA Lifesciences, on: ‘Developing a robust affinity tag platform using engineered streptavidin’.

Protein 59

Protein Antibody Engineer Scientist 59

Drug Discovery World

NOVEMBER 9, 2023

Esperanza Rivera de Torre, PhD, Assistant Professor, Center for Antibody Technologies, Department of Bioengineering, Technical University of Denmark, on: ‘Venom on demand: optimising snake toxin yield, folding, and purity in E coli and P pastoris with biotinylation, solubility, and purification tags’.

Engineer 52

Engineer Antibody Protein In-Vivo 52